Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas

被引：0

作者：

Hu, Bei ^{[1
]}

Korsos, Victoria ^{[2
]}

Palomba, M. Lia ^{[2
,3
]}

机构：

[1] Wake Forest Sch Med, Atrium Hlth Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC 28202 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Cellular Therapy Serv, New York, NY USA

[3] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY USA

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 14卷

关键词：

chimeric antigen receptor T cell therapy (CAR T cell therapy); diffuse large B cell lymphoma (DLBCL); high grade B cell lymphoma; mantle cell lymphoma (MCL); relapsed and refractory lymphoma; CENTRAL-NERVOUS-SYSTEM; AXICABTAGENE CILOLEUCEL; COST-EFFECTIVENESS; BREXUCABTAGENE AUTOLEUCEL; PREDICTIVE FACTORS; OUTCOMES; MULTICENTER; INFLAMMATION; PERSISTENCE; IBRUTINIB;

D O I：

10.3389/fonc.2024.1394057

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach in the treatment of lymphoma. This review article provides an overview of the four FDA-approved CAR T-cell products for aggressive B-cell lymphoma, including diffuse large B-cell lymphoma and mantle cell lymphoma, highlighting their efficacy and toxicity as well as discussing future directions.

引用

页数：13

共 50 条

[31] Chimeric Antigen Receptor T-Cell Therapy
Ogba, Ndiya
Arwood, Nicole M.
Bartlett, Nancy L.
Bloom, Mara
Brown, Patrick
Brown, Christine
Budde, Elizabeth Lihua
Carlson, Robert
Farnia, Stephanie
Fry, Terry J.
Garber, Morgan
Gardner, Rebecca A.
Gurschick, Lauren
Kropf, Patricia
Reitan, Jeff J.
Sauter, Craig
Shah, Bijal
Shpall, Elizabeth J.
Rosen, Steven T.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (09): : 1093 - 1106
[32] Chimeric Antigen Receptor T-Cell Therapy
Rasheed, Azgar Abdul
Koyyala, Venkata Pradeep Babu
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2021, 42 (01) : 89 - 92
[33] Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
Yin, Zixun
Zhang, Ya
Wang, Xin
BIOMARKER RESEARCH, 2021, 9 (01)
[34] Cytomegalovirus impact in b-cell lymphoma patients treated with chimeric antigen receptor t-cell therapy
Marquez-Algaba, E.
Pernas, B.
Esperalba, J.
Los-Arcos, I.
Carpio, C.
Iacoboni, G.
Barba, P.
Ruiz-Camps, I.
BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 134 - 134
[35] Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies
Kim, Seok Jin
Yoon, Sang Eun
Kim, Won Seog
ANNALS OF LABORATORY MEDICINE, 2024, 44 (03) : 210 - 221
[36] Bilateral Cytomegalovirus Retinitis After Chimeric Antigen Receptor T-cell Therapy for B-cell Lymphoma
Meller, Leo
Jagadeesh, Vasan
Wilson, Katherine
Oca, Michael C.
Sestak, Timothy
Scott, Nathan
CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
[37] Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
Zixun Yin
Ya Zhang
Xin Wang
Biomarker Research, 9
[38] Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas
Muhsen, Ibrahim N.
Hill, LaQuisa C.
Ramos, Carlos A.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (06) : 1107 - 1124
[39] Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel
Viardot, Andreas
Wais, Verena
Sala, Elisa
Koerper, Sixten
CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 2393 - 2404
[40] Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
Camacho-Arteaga, Lina
Iacoboni, Gloria
Kwon, Mi
Bailen, Rebeca
Hernani, Rafael
Benzaquen, Ana
Lopez-Corral, Lucia
Perez-Lopez, Estefania
Leguizamo-Martinez, Lina Maria
Calvo-Orteu, Maria
Guerreiro, Manuel
Balaguer-Rosello, Aitana
Alonso-Martinez, Carla
Vidal, Xavier
Barba, Pere
Agusti, Antonia
JAMA NETWORK OPEN, 2025, 8 (02)

← 1 2 3 4 5 →